The Phase I segment of the trial aims to identify the optimal dose of the vaccine for booster vaccination, involving 50 participants. Credit: Hakan Nural on Unsplash.

Entos Pharmaceuticals and its partner Aegis Life have announced the first subject dosing in the Phase I/II clinical trial of Covigenix VAX-002 as a booster vaccine for Covid-19.

The first subject was dosed at a Quebec site.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The trial is sponsored by Entos and overseen by Calian. It is conducted by DIEX Recherche.

It is underway at 12 locations across Canada, including sites in Ontario, Alberta, Quebec and Nova Scotia.

The Phase I segment of the trial aims to identify the optimal dose of Covigenix VAX-002 for booster vaccination, involving 50 participants.

See Also:

The Phase II portion will assess the safety and immune response of the chosen dose in 250 participants.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Entos Pharmaceuticals CEO John Lewis said: “We’re excited to announce the first patient dosed in the Phase I/II trial of our Covid-19 DNA vaccine booster candidate.

“This milestone brings us closer to providing protection against the still-emerging SARS-CoV-2 omicron variants to people in North America, as well as developing countries in need of fridge-stable vaccines.”

Covigenix VAX-002 uses the Entos’ Fusogenix PLV delivery system and plasmid DNA designed to produce key SARS-CoV-2 antigens, targeting the current omicron variants.

Aegis holds the global rights to the vaccine outside Canada and continues to support the trials as a commercialisation partner for the Entos Fusogenix PLV platform.

Entos is also advancing other genetic medicine programmes, including candidates for partnered initiatives and future therapies for rare diseases, eye and ophthalmic conditions, cancer, and infectious diseases.

Entos Pharmaceuticals CMO Steve Chen said: “Covid-19 will remain a public health issue, as evidenced in this summer’s surge of infections.

“Leveraging plasmid DNA cargo, Covigenix VAX-002 has the potential to offer a more durable alternative to what is currently available.”

In June this year, Health Canada granted approval to Entos Pharmaceuticals for launching a Phase I/II trial of its investigational Covid-19 vaccine booster, Covigenix VAX-002.